Hello, everyone, and thank you for joining 111's Conference Call Today. On the call today from the company are Dr. Gang Yu, Co-Founder and Executive Chairman, Mr. Junling Liu, Co-Founder, Chairman, and CEO, Mr. Luke Chen, CFO, and 111's major subsidiary, and Mr. Harvey Wang, COO. As a reminder, today's conference call is being broadcast live via webcast. The company's earnings press release was distributed earlier today, and together with the earnings presentation, are available on the company's IR website. Before the conference call gets started, let me remind you that this call may contain forward-looking statements made under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.
Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known and unknown risks, uncertainties, and other factors, all of which would cause actual results to differ materially. For more information about these risks, please refer to the company's filings with the SEC. One-One-One does not undertake any obligation to update any forward-looking statements as a result of new information, future events, or otherwise, except as required under applicable law. Please note that all numbers are in RMB, and all comparisons refer to year-over-year comparisons, unless otherwise stated. Please also refer to the earnings press release for detailed information of the comparative financial performance on a year-over-year basis. With that, I will turn the call over to One-One-One's CEO, Mr. Junling Liu.
Good morning and good evening. Thank you for joining our third quarter 2023 earnings call. The information we will be discussing is also available in the slides that were posted earlier today on the company's website, and I encourage you to download the presentation as well as the earnings report from our investor relations website at ir.oneoneone.com.cn. I will start by offering an overview of the broader economy landscape, followed by a comprehensive examination of our recent operational achievements. Furthermore, I will discuss our ongoing dedication to advancing industrial digitization, boosting revenue, strengthening our upstream supply capabilities, improving operational efficiency, and outlining our future strategic direction. Afterwards, our Chief Financial Officer, Mr. Luke Chen, will deliver an in-depth analysis of our financial results, ensuring a comprehensive understanding of our company's financial health. Now, let me start with the macro situation in our industry.
While the hospital distribution market in China experienced a modest year-on-year contraction of 2%-5% in 2022, the out-of-hospital pharmaceutical distribution market has witnessed a striking and a continuous upsurge. A detailed analysis by Frost & Sullivan highlights this robust growth, revealing an escalation from CNY 371.6 billion in 2018 to a remarkable CNY 639.7 billion by 2022, marking a compound annual growth rate of 14.5%. This impressive expression is not merely a short-term phenomenon, but is projected to maintain its momentum. Forecasts suggest the market will soar to an estimated CNY 1 trillion by 2027, sustaining a vigorous CAGR of 9.6%.
This exponential growth indicates a paradigm shift in China's healthcare market dynamics, with the out-of-hospital sector poised to command almost half of the healthcare market share by 2026. Its contribution, amounting to nearly 50%, is set to become a cornerstone in shaping the overall healthcare landscape in China, reflecting a significant shift in consumer preferences and the healthcare delivery model. However, in the third quarter of 2023, the pharmaceutical industry in the out-of-hospital market faced challenges. According to Sinopharm Health, total sales revenue in the retail pharmacy market declined compared to last year, primarily attributed to a decline in sales volume. First of all, in the third quarter, there was more competition among retail pharmacies as they expanded due to relaxed spacing restrictions, which led to a drop in the number of orders per store.
Second, and more importantly, the gradual resolution of existing inventory issues for four categories of pharmaceuticals, namely fever-reducing, cough-suppressing, antiviral, and antibiotics medications, has led up to slow inventory digestion. These inventory challenges had built up over time, especially due to the backdrop of the pandemic at the end of the previous year that led to concentrated consumer buying behavior in late 2022. Additionally, the impact of external factors, such as global supply chain disruptions and Anti-Corruption Act, continued to influence the pharmaceutical sector, underscoring the importance of agility and preparedness in the industry. Despite the challenges in the macroeconomy as well as retail pharmacy business, we have managed to deliver net revenue growth of 9.5% year-over-year, reaching CNY 3.7 billion. This represents the 21st consecutive quarter of year-over-year progression for 111 since our NASDAQ IPO.
Our gross segment profit faced a temporary challenge due to our concerted efforts to digest the inventory of anti-COVID related medicines, resulting in a modest 5.6 decrease compared to the same period last year. However, our continued efforts to enhance operational efficiency have yielded promising results, as evidenced by the reduction in total operating expenses as a percentage of net revenues to 7.4% this quarter, compared to 8.4% in the same quarter of the previous year. More specifically, as 111's business continues to expand and our technological capabilities advance, our operational efficiency remains on a positive trajectory. Notably, as revenues have risen, we have achieved a reduction in the proportion of sales and the marketing expenses, which now account for 2.6% this quarter, compared to 3.2% in the corresponding quarter of the previous year.
Furthermore, the general and administrative costs relative to net revenues have decreased to 1.3% this quarter, down from 1.4% during the same period last year. Additionally, our technology-related expenses have decreased to 0.7% this quarter, down from 0.9% in the same period last year. Meanwhile, through optimization, our fulfillment costs were reduced from 3% to 2.8% relative to net revenues as well. This positive trend reflects our commitment to prudent financial management and sets a solid foundation for our future growth.
As a result, it's important to note that our operational loss as a percentage of net revenues improved to 2.2%, compared to 2.4% in the corresponding quarter of the prior year, and our non-GAAP operational loss remained stable at 1.5% of net revenues, consistent with the performance in the third quarter over the previous year, underscoring our commitment to efficient management and our ability to maintain healthy operational margins. Please allow me a moment to underscore the progress we've achieved in our operations during the third quarter. This period has been characterized by our continued focus on advancing digitization and improving our management processes, laying the groundwork for even more substantial returns on this strategic investment in the times ahead.
As you may know, the previous pharmaceutical industry was plagued by a complex and convoluted multilayer structure, riddled with inefficiencies and numerous drawbacks. However, in this era of digitization, our innovative approach is ushering in a transformative change. Through our cutting-edge data, direct linkage, and the digital empowerment initiatives, pharmaceutical companies, pharmacies, and consumers alike are reaping significant benefits, such as better pricing, better operational efficiencies, and a better visibility and a mutual understanding. This paradigm shift has brought about the much-needed deintermediation of the industrial supply chain, streamlining processes and eliminating unnecessary intermediaries. Furthermore, transaction automation has revolutionized the way business is conducted, enhancing efficiency and reducing errors. Intelligent service, driven by data-driven insights and artificial intelligence, is empowering stakeholders with personalized and efficient solutions.
The fundamental driver of our business growth lies in the establishment of a positive feedback loop that seamlessly integrates technology into our supply chain, demand, and operations. Our success is rooted in the ability to harness the power of technology to enhance our demand services, ensuring that we can efficiently meet customer needs and preferences. Simultaneously, we leverage technology to optimize our supply services, ensuring the timely and cost-effective delivery of goods and services. The synergy between these aspects of our business is further amplified by technology-driven operational upgrades, enabling us to operate with precision and agility. Thus, in our pursuit of operational excellence, we have harnessed the power of technology to elevate our end-to-end supply chain digitization efforts, resulting in enhanced decision quality and operational efficiency.... Through a full digital management system, we've achieved comprehensive real-time data management, ensuring 24-hour access to critical insights.
Our multi-section and a multi-angle automatic BI analysis of business information further empowers us to make data-driven decisions swiftly. Our PIS, which is the intelligent pricing system, utilizes big data models for automatic price adjustments, streamlining processes, and improving accuracy. Additionally, our smart supply chain features innovations like stock relocation systems, intelligent purchasing inquiries, and the logistics track optimization, collectively transforming our supply chain operations and driving efficiency gains across the board. Second, our commitment to technological innovation has given rise to a comprehensive platform that serves as a game changer in the realm of category and pricing management, fostering closer collaboration between pharmaceutical companies and the retailers. Within this cutting-edge ecosystem, our pharmaceutical enterprise services introduce a transformative approach to data analysis. Our Telescope product allows for the precise visualization of distribution statuses across a network of over 20,000 endpoints nationwide.
It offers insight for market penetration analytics, spanning 34 provinces and 600+ cities, while also providing a clear year-long overview of sales data trends. Complementing this, our JBP Merchant Services are a testament to operational efficiency. They automate transaction processes, significantly reducing stock-to-shelf times from hours to mere minutes, and streamlining replenishment efforts in the same fashion. In addition, our MP merchant services empower retailers with invaluable tools for success. Sales visualization is made accessible to merchants who can query data thousands of times daily via mobile terminals, enabling them to make data-driven decisions efficiently. In essence, the comprehensive platform redefines how pharmaceutical companies and the retailers interact and operate, offering a dynamic and technology-driven solution that enhances efficiency and the transparency throughout the supply chain.
Third, our strategic integration of technology and demand analysis places a strong emphasis on a significant upgrade of demand volume. Through intelligent demand analysis, exemplified by the Dynamic Catalog, we continuously update our understanding of customer demand by leveraging both company and industry data. This greatly enhances our assortment decisions, giving priority to top demanded goods and tailoring offerings regionally to meet unique demands. Furthermore, our smart sales initiative, empowered by the Eagle Eye tool, enhance customer engagement and transform marketing efforts for increased efficiency. In parallel, we empower and optimize pharmacy operations by analyzing customer segments, providing product demand service guidance for B2B to C success, implementing a smart sourcing system, offering cloud prescription services, deploying the pharmacy operation analysis board, and leveraging pharmacy CRM, among other innovations.
This holistic approach not only identifies pharmacy needs with precision, but also equips pharmacy operations with the tools needed to thrive in a dynamic market landscape. Through our unwavering commitment to innovation and the successful implementation of the aforementioned initiatives, we have garnered widespread recognition, cooperation opportunities, and received prestigious awards from industry authorities and organizations. To name a few, the strategic partnership formed between Tencent and us in June has set the stage for a robust collaboration aimed at enhancing accessibility of online pharmaceutical services. As a result of this collaboration, significant infrastructure work was carried out during the third quarter, laying a solid foundation for a more streamlined and efficient operation.
This strategic cooperation agreement, sealed with Tencent Health, spans areas such as pharmacy digital services, pharmaceutical digital marketing, and online medical intelligence services, with the overarching objective of establishing a pharmaceutical plus internet digital upgrade industry paradigm. Leveraging Tencent's technological prowess in cloud computing, big data, artificial intelligence, and its extensive reach in the consumer internet sector, this partnership is instrumental in bolstering 111's digital infrastructure and smart pharmacy retail capabilities. We anticipate that, as we enter the fourth quarter, tangible outcomes from this partnership, including improved pharmaceutical sales efficiency and substantial support for pharmaceutical companies in their digital transformation journey. This strategic move represents a pivotal step forward for 111's digitization strategy, underscoring our unwavering commitment to innovation and growth. Meanwhile, on August the eighth, the Ministry of Commerce of China announced on its official website, the list of e-commerce demonstration enterprises, among which 111, Inc.
was included. This time, a total of 132 enterprises nationwide were selected, and only 13 enterprises from Shanghai, including 111, Inc., were honored with this recognition. On August eleventh, we were honored to have our case on leveraging digitization for pharmaceutical full channel commercialization, selected for the 2023 supply chain management services and a manufacturing integration category within the fourth China Industrial Product Online Trading Festival. 111, Inc. has tailored digital solutions for full channel pharmaceutical commercialization for our pharmaceutical firms. Through services like warehousing, marketing, distribution, after-sales support, and patient management, we have enhanced the marketing accessibility of high-quality medicine products, benefiting a broader patient base. Concurrently, we've continued to upgrade our own digital capabilities, improving efficiency and service levels, while breaking down information barriers across the pharmaceutical supply chain.
By harnessing the power of digitization, we empower stakeholders throughout the pharmaceutical ecosystem, driving industry optimization, enhancement, and the creation of greater societal value. Also, in August, 111 was recognized as one of the top 10 pharmaceutical retail e-commerce platforms in 2023, and it received the prestigious CPEO Gold Award at the sixteenth China Pharmaceutical Ecology Conference. Over the years, our dedicated work in the pharmaceutical and medical sectors has transformed us from a traditional e-commerce platform into a digital healthcare integrated service platform. We have seamlessly integrated online and offline services to create an ecosystem connecting hospitals, pharmaceutical companies, pharmacies, patients, doctors, and more, offering end-to-end services, covering medicine plus healthcare payments.
With our core technological capabilities, industry-leading integrated online and offline intelligent supply chain platforms, and a multi-channel digital systems, we will empower stakeholders throughout the healthcare industry, create new value, provide patients with more convenient and high-quality healthcare products and services, and continuously enhance efficiency through supply chain optimization, contributing to digital transformation and upgrading of the healthcare and the pharmaceutical industry. In September, our 1 Pharmacy Technology team achieved a significant milestone by securing three patents, highlighting our commitment to innovation in the healthcare sector. The first patent pertains to a cutting-edge predictive system for pharmacy operations. This innovative system leverages advanced data analytics and machine learning techniques to forecast various aspects of pharmacy management, including inventory optimization, patient demand trends, and resource allocation.
By harnessing the power of predictive analytics, we aim to enhance the efficiency and responsiveness of our pharmacy operations, ensuring that patients receive the right medications when they need them. The second patent is related to a system for estimating the advantages of specific pharmaceutical products. This system employs sophisticated algorithms to analyze a range of factors, such as clinical efficacy, cost-effectiveness, and patient outcomes, to determine the superior attributes of certain medications. By accurately identifying high-value pharmaceuticals, we can better guide both healthcare professionals and patients toward making informed decisions regarding treatment options. Our third patent pertains to a low-code platform development method and system. In the context of pharmaceutical distribution and retail business, this technology can significantly simplify allocation development processes, leading to improved operational efficiency and adaptability.
It allows for the rapid creation of customized applications tailored to specific needs, enhancing various aspects of the pharmaceutical supply chain, including inventory management, order processing, and customer engagement. This innovation holds great promises for optimizing pharmaceutical distribution and retail operations, making them more agile and responsive to market dynamics and regulatory changes. These patents underscore our continuous efforts to drive innovation in the healthcare industry. They're not only a testament to our commitment to delivering enhanced services to patients and our healthcare providers, but also highlight our dedication to staying at the forefront of technological advancements in the field. These systems will play a pivotal role in improving the overall healthcare experience for individuals, and contribute to the broader transformation of the healthcare landscape.
In October, with our profound understanding of digitization in the internet healthcare sector, we were honored to receive the 2023 China Digital Breakthrough Practice Award from the China Management Model 5+ Forum. This prestigious award recognizes our outstanding achievements in corporate digital transformation. The selection criteria prioritize long-term value, stakeholder interests, and continuous innovation across our business operations, internal management, and collaborative efforts along the industrial value chain. Through our digital capabilities, we have ensured nationwide access to essential medicines, empowered patients with knowledge about innovative drugs, reduced medication costs, improved cost-effectiveness for patients, and are continued to addressing healthcare accessibility and affordability challenges. To sum up, for Q3, we have remained steadfast in our commitment to the core principles of value creation, customer centricity, and the strengthening of our supplier relations across the organization.
Building on the success of our recently established in-house advisory department from the previous quarter, we're pleased to report even more significant strides in this quarter. This dedicated team has continued to drive strategic advancements across various sectors with a deep focus on customer needs analysis. Through their efforts, we have fine-tuned our product portfolio to align even more precisely with market trends and preferences. By diligently monitoring evolving market dynamics and leveraging real-time customer feedback, we have successfully recalibrated our pricing strategies. Moreover, the department's contributions extend to refining internal resource allocation, streamlining procedural workflows, and enhancing overall operational efficiency. As a result of these concerted efforts, we're delighted to announce that this quarter we have consistently met and often exceeded customer expectations, implemented sustainable pricing models, and have maintained adept resource management across the organization.
Now, let me spend a moment to talk about our future growth initiatives. One, grow JBP business segment to significantly, significantly increase selection and enhance customer experience. Next quarter, we will continue to allocate resources to strengthen our JBP business, which is the consignment model, as a cornerstone of operational excellence and efficiency. Through this approach, we aim to rapidly incentivize an increasing number of vendors to place their products within our warehouses, resulting in a seamless alignment with customer demands. The JBP model enables us to take full control of the logistics, ensuring a superior customer experience compared to the MP model. We understand that precision is paramount, and we will leverage market data and analytics to guide and refine our strategies continually. Moreover, our commitment extends to building a mutually beneficial ecosystem, fostering strong partnerships with both upstream vendors and downstream pharmacies.
This collaborative approach will not only enhance our competitiveness, but also contribute to the overall growth and success of all stakeholders within our supply chain network. 2, to deepen strategic relations with upstream pharmaceutical customers. We will keep strategically allocating our first-party resources to sharpen our focus on critical areas that warrant dedicated attention, such as direct sourcing from pharmaceutical companies and the sourcing of high-margin products. By doing so, we aim to optimize our efforts and the resources in these key domains, ensuring that we can efficiently meet the specific demands of our customers, and strengthen our partnerships with pharmaceutical manufacturers, and lower our procurement costs. This strategic approach allows us to further enhance the quality and variety of our offerings, while maintaining a keen eye on cost effectiveness and profitability.
Furthermore, this collaborative effort among our first-party resources, JBP, and the marketplace segments, will complement each other synergistically, creating a comprehensive and a well-rounded approach to serve our customers effectively and efficiently. Three, AI-driven customer experience upgrade. We are committed to leveraging AI-driven platform models to deliver better outcomes for our end customers and to drive business growth for all stakeholders. Through the implementation of advanced algorithms, our AI system is designed to identify the best bargains for customers, ensuring that they save money while enjoying a wide array of choices. Simultaneously, this technology has built-in self-learning capabilities and will continuously improve output for customers. This approach fosters a balanced ecosystem where customers benefit from cost savings, vendors gain increased visibility and business opportunities, and the overall demands are fulfilled with the best supply.
By embracing AI-driven solutions, we're taking significant strides toward reshaping the supply and demand value chain for our industry. Four, employing AI tools for pricing. We are embracing AI as a pivotal tool to shape our pricing strategies for both first-party business and our JBP and MP partners to navigate our marketplace effectively. With the aid of AI algorithms, we can make data-driven decisions that ensure competitive pricing for our products and services. This technology allows us to fine-tune our procurement processes, identifying the most cost-effective sources and channels. Additionally, our AI-driven approach extends its benefit to our partners, assisting them in understanding how to capitalize on the dynamic traffic within our ecosystem while making informed pricing choices. By harnessing the power of AI, we're not only enhancing our own operations, but also equipping our partners with the tools they need to thrive in our marketplace.
Five, relentless commitment to enhancing operational efficiency. We're dedicated to achieving operational excellence through a strategic blend of technology integration and a workforce optimization. Our ongoing dialogues with external vendors, particularly in logistics, aim to secure favorable terms that streamline our supply chain and reduce overhead costs. Additionally, we prioritize the refinement of management skills and decision-making capabilities, recognizing their direct impact on operational prowess. By meticulously addressing these areas, we are positioned to significantly reduce operational costs, opening the path to sustained growth and prosperity. Six, organizational optimization to drive better business results. We're embarking on a comprehensive organizational upgrade to better align ourselves with the evolving business landscape and the new challenges it presents. As part of this initiative, we're strategically restructuring our team to ensure they are agile and responsive to market dynamics.
This restructuring will involve optimizing our staff distribution, leveraging the right talent in the right roles, and fostering a culture of innovation and adaptability. By embracing these challenge, these changes, we aim to create a more nimble and efficient organization that is well-equipped to tackle the challenges of the future, while delivering exceptional value to our customers and partners. Seven, pledging to digital transformation. Our unwavering commitment to digital transformation is poised to yield substantial dividends, particularly in the upcoming Q4. Through the seamless integration of digital solutions, we are refining our methodologies and enhancing operational efficiency, setting the stage for groundbreaking initiatives. Our ongoing cooperation with Tencent is expected to bear fruits, contributing to our digital prowess. Furthermore, we anticipate obtaining another patent in Q4, further strengthening our position as an agile and a competitive entity.
As we intensify our focus on digital strategies and foster a culture of continuous innovation, we are well-positioned for sustained growth in the rapidly evolving healthcare landscape. In closing, despite the hurdles and triumphs, 111 remains steadfast in its commitment to spearheading advancements in the healthcare sector. We continue to champion transformative initiatives and uphold a commitment to excellence in service delivery within the dynamic landscape of our industry. We extend our sincere gratitude to all the investors who have steadfastly supported us throughout our journey. I will now pass the call to Mr. Luke Chen to provide a comprehensive overview of our financial results. Thank you.
Thank you, Jimmy, and good morning or evening, everyone. Moving to the financials, my prepared remarks were focused on a few key business and financial highlights.
... You can refer to the details of the third quarter 2023 results from Slide 22-25 in Section 2 of our presentation. Again, our comparisons are year-over-year, and all numbers are in RMB, unless otherwise stated. Despite the challenges in the macroeconomy as well as the retail pharmacy business, our total net revenues for the quarter grew 9.5% to CNY 3.7 billion, which was mainly attributed to our B2B segment growth, revenue growth at 10.1%. As we made efforts to digest the inventory of COVID-related medicines, gross segment profit for the quarter decreased 5.6% to CNY 190.6 million. Gross segment margin was down from 6% to 5.2% for the quarter. We have been consistently improving our operation efficiency and have gained positive results.
Our total operating expenses for the quarter decreased 4.1% to CNY 271 million. As a percentage of net revenue, total operating expenses for the quarter was down to 7.4% from 8.4%. Fulfillment expenses as a percentage of net revenue for the quarter were down to 2.8% from 3% in the same quarter of last year. Sales and marketing expenses as a percentage of net revenue for the quarter was 2.6%, down from 3.2% in the same quarter of last year. The general and administrative expenses as a percentage of net revenues accounted for 1.3%, down from 1.4% in the same quarter of last year.
Technology expenses accounted for 0.7% of net revenue, down from 0.9% in the same quarter of last year. As a result, net GAAP loss from operations was CNY 54 million, compared to CNY 48.7 million in the same quarter of last year. As a percentage of net revenues, net GAAP loss from operations accounted for 1.5% in the quarter, which was same as last year. Net GAAP net loss attributable to ordinary shareholders was CNY 66.9 million, compared to CNY 69.9 million in the same quarter of last year. As a percentage of net revenue, net GAAP net loss attributable to ordinary shareholders decreased to 1.8% in this quarter from 1.9% in the same quarter of last year.
Please refer to Slide 26-30 of the appendix section for selected financial statements. A quick note on our cash position. As of September 30, 2023, we had cash and cash equivalents, restricted cash and short-term investments of CNY 876.6 million. As of the date of this earnings release, we have a total outstanding amount of one point one billion, which has been included in the balance of redeemable non-controlling interest and accrued expenses and other current liabilities owed to a group of investors of One Pharmacy Technology, pursuant to their equity investment made in 2020, as previously disclosed.
As of the date of this earnings release, we have received a redemption request from certain of such investors for a total redemption amount of CNY 0.2 billion, in accordance with the terms of their initial investment in One Pharmacy Technology. We are currently in the process of negotiating with these investors and other relevant stakeholders regarding the repayment and/or restructuring of such redemption obligations. This concludes our prepared remarks. Thank you. Operator, we are now ready to begin the Q&A session.
Thank you. If you wish to ask a question, please press star then one on your telephone and wait for your name to be announced. If you wish to cancel your request, please press star then two. If you are on a speakerphone, please pick up the handset to ask your question. Again, that's star one. At this time, we will pause momentarily to assemble our roster. The first question today comes from Xipeng Feng with CICC. Please go ahead.
Hi, thank you for taking my questions, and congratulations on the company progress. Well, I have two questions, actually, and my first question is about fundamentals. As we notice, the operating expense ratio of 111 has been decreasing. So what is the main reason behind this trend, and will that continue to decrease in the future? And my second question is about business. Just as you mentioned before, would you please discuss a little bit more about the progress have been made recently in the company's investment in technology? And that's my question. Thanks.
Okay. Xipeng, thank you. Thank you for the question. I'll take your first one regarding the operating expenses. In the previous years, we have been continuously putting our efforts to enhance our operational efficiency. And as we just announced, the overall operating expenses have been reduced to 7.4% this quarter.
... and compared to 8.4% in Q3 last year. So within the key, the key components of the operating expenses, the sales and marketing has been reduced to 2.6% this quarter, compared to 3.2% of last Q3. And our G&A has decreased to 1.3% from 1.4%. Our technology-related expenses has decreased to 0.7% and down from 0.9% of last Q3. And furthermore, our fulfillment cost has reduced from 3.0%- 2.8%. So you can see this, the important element of our operating efficiency and reduction of the costs occur in all functions across our organization.
We believe with the increase of our sales volume and also the implementation of new AI technology in our daily operations, that we will continue to see those reductions on all areas in our operating. Thank you.
Let me take the second question about technology investment. Okay. I would say that our technology investment in technology has achieved a remarkable progress lately. Let me demonstrate this through a few data points. One is that our company has been awarded the 13th China Digital Management Excellence Award. The second is that our company has been honored with the title of the Best Data Innovation Benchmark Case, the 2nd China Data Elements Annual Awards. We were awarded specifically in the field of medical industry master data applications. Pini has mentioned that we have recently acquired three new patents. We also have made progress in AI applications. For example, 80% of both internal and external customer service inquiries are handled by AI algorithms.
They are powered by internal knowledge space and by utilization of the OpenAI platform, enabling efficient and GPT-based IT customer support services. I hope this answers the question about technology investment.
That's very clear and helpful, and thanks for the sharing, and congratulations again on the company's progress. Thank you.
The next question comes from Kevin Tong, an individual investor. Please go ahead.
Good evening. Thank you for the sharing. My question is, how did the company intend a twenty-first consecutive quarter of YoY growth since NASDAQ IPO? And will this growth continue especially this level achieved in the last quarter of the previous year? Thank you.
Thank you, Kevin. Let me think. I think there are a few things we did right to achieve consecutive 21 quarters of year-over-year growth. I think, first of all, the culture of the company is always focusing on customer experience. Our decision-making is always centered around customer experience. Some of the projects, when we assess, we need to figure out what kind of improvement that's gonna bring to customer experience. And secondly, we have always had a strategy to, first of all, building infrastructure, and secondly, building scale. And with the infrastructure and scale, we'll be able to achieve profitability. And obviously, that's yielding results. And, you know, the other contributing factor to the continuous growth is really our technology.
You know, as I mentioned, we were awarded another three patents last quarter. That says a lot about our continuous focus. Let me remind you, when we first IPO'd back in 2018, back then, our revenue was less than CNY 1 billion. It was CNY 900 million something. Of course, you know, this year or last year, we achieved CNY 13.5 billion, and this year, we anticipate, you know, in the neighborhood of CNY 15 billion. So we have absolutely come a long way, and we look forward to really reporting even better results in future quarters. Thank you, Kevin.
... Thank you, and congrats, again.
The next question comes from Tom Craig with Cornerstone Investment. Please go ahead.
Hi, this is Tom. Congratulations for your last quarter's performance. I have two questions. The first is, after effectively adjusting and normalizing the backlog of inventory in the market, how will 111, Inc. navigate the market environment that is both promising in the long term, but increasingly competitive? Specifically, what strategic measures will the company take to enhance the breadth and depth of cooperation with upstream and downstream customers? And my second question is: What are the key drivers behind the decreasing gross segment profit this quarter, and how will 111, Inc. adjust these issues? Thank you.
Yeah, Tom, I think, as you mentioned, you know, there is a huge backlog across the whole industry because of the COVID-related medicine. And, you know, the whole industry suffered in the second quarter and the third quarter. And, we're very pleased to report that, we have normalized our inventory, and, you know, obviously, moving forward, you mentioned about, competition. Our view has always been, whether you like it or not, the competition will always be there. So we might as well embrace it. So, you know, we should take a very positive view. Competition should be good for us, because that's gonna force us to really focus on customer experience, focusing on, you know, the value creation.
You know, as I mentioned in my script, I think, let me just highlight that, we will be really focusing on the expansion of our JBP business and the first-party business on the supply side. This will mean that we're gonna have a strategy of both a centralized approach and a decentralized approach. So, by way of being centralized, that means we're gonna have dedicated teams focusing on the big pharmaceutical companies, where we need to build really direct sourcing, where we really need to source high-margin products, and, and also really securing supply and better pricing. So, you know, we have made tremendous progress over the years, and we're gonna continue to focus on that. So this is the centralized approach.
And the other approach to complement that is the decentralized. That means we're gonna really leverage the market forces, especially our JBP partners. You know, those commercial vendors can place their inventory into our fulfillment centers, and then we can deliver to our downstream pharmacy customers. And by having them really contributing to really the selection experience for our customers downstream, you know, by purely doing first party centralized, it's gonna take a much longer time, and it's gonna be very costly. And by leveraging those vendors, it's going to be much faster and much more cost-effective. And we're gonna have a far wider selection for our downstream customers to choose from.
So, we're gonna have separate teams focusing on those different business metrics, and we believe that by focusing on both the centralized and the decentralized approaches, it's gonna bring really great benefits. We have already seen that, and you know, Q3, we had the backlog cleared. You know, we feel pretty light, and I really look forward to reporting Q4 results to our investors, including you, Tom. Thank you.
Yeah, Tom, regarding your second question of the gross profit. Yeah, the retail pharmacy of the past Q3 declined completely in entire China. So the very important reason is, as just Jimmy mentioned, the existing inventory issue, which was sold during the peak of COVID restriction several months ago. For example, a lot of families, including myself, still have quite some, for example, like, ibuprofen and some Chinese medicine, like, Lianhua Qingwen, et cetera, at home, and which are going to be expired. And this inventory issue is across the country, so which leads to a decline in the entire pharmacy retail market. But despite all these challenges, we have managed to deliver a 9.5% year-over-year revenue growth.
The issue of our growth segment profit actually is a temporary challenge, and regarding this, the inventory, which we have managed to resolve this anti-COVID related medicine. So it's a temporary problem. We have already resolved the inventory issue. So going forward, we will still go back to our strategy towards a much more healthy business, and first, to reduce our procurement cost through our direct sourcing from those pharmaceutical companies. And also secondarily, to optimize our product assortment and structure, and also to further utilize our strength on our digital technology and to promote our digital platform, as well as our SaaS services to all our upstream and downstream customers. All these strategy will bring us a much more healthy business.
And also, I believe we are going to see a better margin performance moving forward. Thank you.
Thank you.
Thank you.
The next question comes from Jada Wu with Arbor Growth Capital. Please go ahead.
Hi, everyone. This is Jada Wu from Arbor Growth Capital. Congratulations on your success last quarter. My following question will revolve around the company's future outlook. First, please talk about the company's thoughts and layout in the field of artificial intelligence. Second, what will be the company's operational focus going forward? Thank you.
Jada, thank you. Let me see if I can address your question around artificial intelligence. And I think in my script and also Dr. Yu just mentioned there are a few things we're doing, right? So first of all, you know, in terms of customer services we are adopting a lot of those AI elements, and we're making a very good progress in that space. And secondly, you know, when it comes to pricing we have the intelligent pricing system, and the AI plays a huge role. But I wanna talk about a very bold approach, and we have internal project that is underway, and we're already having very encouraging results.
You know, as you can tell, since the launch of the ChatGPT, AI has swept the whole industry, and you know, there are more than 200 large language models that's been built in China. And we don't believe that building a large language model will fit into our business. But what we do have is the 12, 13 years accumulation of industry data. So each day, we have over 1 million queries, you know, over 1 million SKU queries on our platform. And we have our first-party supply, we have our JBP supply, we have our marketplace supply. And obviously, for a single customer to really find the best deal is a very challenging task.
You know, let alone, outside of our platform, they have to do this manually via phone call and so on. So what we're trying to do is, instead of building a large language model, we would like to build a transformer, maybe a mini transformer. It doesn't have to be a full-fledged transformer. We can leverage the established platforms technology, to really bring the best deals to our, let's say, downstream customers when they have those queries. And, you know, it's not because we are so good at AI, it's just because, you know, it so happened that we have probably the best set of industry data. And, you know, it would be foolish not to really utilizing all that to bring great results to our customers.
So the significance of this project and the implication is not only really focused on, you know, building a better demand and a supply ecosystem, and, you know, we can be centered around that. What we are really eyeing is the future. You know, let's say we have a traditional business, we call that, you know, let's say, the traditional commerce. And then, you know, we moved on to e-commerce, but fundamentally that is still the old commerce, you know, except that you bring those products onto the virtual shelf. But it's still a one-way passive kind of commerce. The transaction is basically a one-way traffic. There's nothing much you can do apart from, you know, exhibiting your prices.
But with AI capabilities, especially if it is, you know, generative, we can actually have interactive dialogues with the customers. And especially, you know, when you have promotions, especially, you know, after you accumulated so much data about a particular customer, you know their assortment, you know, the deficiencies, let's say, in their assortment. You know the seasonal changes, you know, what kind of products they need to, you know, let's say, build inventory to anticipate customers' demands and so on. So when winter comes, you know, you know, you know, cough and, you know, catching a cold, influenza would be critical for pharmacies. And by proactively approaching customers, you know, with the precise information, we can bring tremendous value.
Because it's going to be interactive, we can absolutely transform the traditional commerce business to a, let's say, you know, from e-commerce, probably, you know, I'm just trying to name it to find the right word, to AI commerce. You know, which used to be a one-way non-interactive, to a two-way interactive commerce. And you know, it's still very early stage. You know, we cannot claim any really results, but we're extremely excited in this area, and we will continue to explore, and hopefully I can update you in the near future of the progress we'll make. So, I think, Harvey, would you talk about the second question?
Yeah.
Uh, data.
Yeah, data. Regarding your second question on the operational focus, and actually, our focus has actually has remained unchanged. I think, basically, I can conclude with two key message. One is the customer experience, and second is our operational efficiency. So on the customer experience side, first of all, we will further enhance our Dynamic Catalog tool, just as CEO also mentioned in his script, to continuously update our assortment database and enhance assortment decision, and also giving direction to our supply organization on real-time customer demand. And also secondary, we are setting up an omni-channel supply for full selection by our JBP, our marketplace, and also the platform management.
Certainly, on the customer experience, we are launching new technology, including AI, and for example, like, with our smart supply chain system, to make sure much better delivery services to our owners and to our customers. On the operational efficiency part, first of all, we will continue to promote our JBP model to automate the transaction process and also to reduce our partners' inventory cycle. Secondly, we will better manage our marketplace model using the platform, which consists of several thousand vendors that serve our customers.
And also, we are launching the new so-called version of our Price Intelligence System, which also will help us to manage our price in real time and much more effectively. And I think hope I answered your question, Jada.
Thank you. Thank you for your providing such detailed insight. It's quite clear and helpful. Thank you.
Thank you.
The next question comes from Cathy Li with SBS Capital. Please go ahead.
Okay. Congratulations on the growth, and I have two more concerns. First, what are the expected outcomes of the JBP business expansion, and how will it enhance customer experience and operational efficiency? Second, regarding to the supply chain management, what actions have been taken to improve its operational efficiency, and what results are expected from this improvement? Thank you.
Thank you for the question, Cathy. First of all, we know that the JBP business model requires very tight relationship between us and our JBP partners, and it leverages the strength of both. So with such a strong tie, we enjoy much faster selection expansion, a much fuller service coverage, more effective use of our smart supply chain, and less stock shortage. So all these will definitely enhance our customer experience. In addition, with the, you know, the same selection, same SKU will be offered by multiple JBP partners. So through competition, the price will be better for our customers. Regarding operational efficiency, will be improved by two fundamental things. One is that, we'll offer effective data-driven systems to our JBP partners.
... they have a complete visibility and transparency of our supply chain. Second, we have been continuously improve our forecasting systems, inventory management systems, and PIS, price intelligence systems. All these, we share the system functionalities with our partners. So regarding the supply chain management, improvement, let me just use a few examples. Okay. In warehousing, we started a gold partner project. This project strengthened our supplier partnership for faster, more reliable inbound deliveries. It reached more than 50% reduction in inbound exception rates. We also have a warehouse capacity expansion to make more effective use of our existing capacity.
So we have much better layouts and, improved processes, so we improve our warehouse capacity by 6.6%, nearly doubled our SKU, storage, so that this also in turn reduced our rental cost. I also, have other projects for much, you know, more efficient picking, packing, et cetera. Okay, let me mention a couple on the logistics part. So we integrated more than 20 delivery providers for more cost-effective, timely delivery. Achieved, year-to-date more than CNY 7 million cost reduction in delivery. Also, we implemented a digital ordering process and the system, where have more than 400 suppliers participating. Increase, increasing our procurement, team efficiency, so everyone can, in the procurement team associate can manage it, triple their, efficiency.
That means every person can manage three times more SKUs than before. Also, we have a inventory management system, 2.0 upgrade. Improved inventory monitoring, reduced, you know, product out-of-stock rate. Right now, our stock rate dropped to 2.6%, you know. It used to be 5% or 6%. Okay, let me just mention these few examples. Thank you, Cathy.
Thank you for your answers, and, again, congratulations.
The next question comes from Ethan Ling with Iron Harbor Capital. Please go ahead.
Hello. First of all, congratulations for your company's growth. I have a few questions today. First question is, what are company's plans for its OEM product in the future?
OEM? All right. Ethan, I'll take this question. And there are a couple of OEM, what we call it, private label, registered in 111, and we have one JBP for our 1 Drugstore customers, with Royal Glory for our individual store customers and also Lanidia for dietary supplements. And by Q3 this year, we already launched 143 private label SKUs. And of course, there are much more SKUs already in our pipeline. Most of these products have been well accepted by our downstream pharmacy customers. And as you may know, a private label product has been a very important and key margin and revenue contributor of those top KA chain stores.
But for our customers, which are basically a small or medium size chain stores or individual customers, individual stores, they don't have the luxury and capability to establish their own brand. So, our brand, our 111 brand and Guanz hao, Huangj ia, Royal, et cetera, becomes a very attractive solution for them to improve their own margin. Yeah, I hope answered your question.
Yes, thank you. And, the next question is that, I know the company started privatization since last season. What is the current progress of the company's privatization?
Yeah. Ethan, yeah, as you know, the company is undergoing the going private process. To my knowledge, the process is still ongoing. The special committee, consisting of three independent directors, are still evaluating the proposal from the buyers group. And it's for sure they will make relevant announcement according to the SEC rules. As management, we will continue to focus on core business and better serve our customer.
All right. Thank you. And, I have another question: How was the cash flow situation in the third quarter for the company, and what's the current cash position?
Yeah. In terms of cash position, as of September end, we had cash and cash equivalents, restricted cash and short-term investment, amounting to CNY 877 million. So we are also very glad that our operating cash flow and overall cash flow for the quarter has been positive. We have confidence that we will continue to operate with very high efficiency and as well as to generate positive cash flow in the future quarters. Thank you.
That's great to hear. Thank you for answering. That is all my questions.
There are no further questions at this time. I'm gonna hand the call back over to the company for closing remarks.
Well, we thank you, all the investors. So this will conclude our call for our Q3.
Thank you.
Thank you.
In closing, on behalf of the entire 111 management team, we'd like to thank you for your interest and participation in today's call. If you require any further information or have any interest in visiting 111 in Shanghai, China, please let the company know. Thank you for joining us on the call today. This concludes the call.